Keay Nakae
Stock Analyst at Chardan Capital
(4.01)
# 663
Out of 4,412 analysts
144
Total ratings
30.67%
Success rate
19.07%
Average return
Main Sectors:
28 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Maintains: Buy | $25 | $4.33 | +477.37% | 8 | Apr 16, 2024 | |
| NTBL Notable Labs | Maintains: Buy | $9 → $7 | $0.97 | +625.39% | 1 | Apr 15, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $5 | $1.92 | +160.42% | 1 | Apr 4, 2024 | |
| FEMY Femasys | Maintains: Buy | $12 | $1.27 | +844.88% | 8 | Apr 1, 2024 | |
| OMGA Omega Therapeutics | Maintains: Buy | $12 → $7 | $2.27 | +208.37% | 4 | Apr 1, 2024 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.39 | +355.58% | 5 | Mar 28, 2024 | |
| GANX Gain Therapeutics | Reiterates: Buy | $6 | $3.03 | +98.02% | 5 | Mar 27, 2024 | |
| COYA Coya Therapeutics | Maintains: Buy | $11 → $14 | $8.60 | +62.79% | 9 | Mar 20, 2024 | |
| SLN Silence Therapeutics | Maintains: Buy | $26 → $42 | $21.61 | +94.40% | 5 | Mar 14, 2024 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $2 → $2.5 | $1.94 | +28.87% | 8 | Mar 14, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $20 → $31 | $24.73 | +25.35% | 4 | Mar 8, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $10 → $8 | $0.83 | +869.70% | 4 | Mar 6, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $23 → $33 | $24.36 | +35.47% | 7 | Mar 5, 2024 | |
| ABUS Arbutus Biopharma | Reiterates: Buy | $4 | $2.73 | +46.52% | 6 | Mar 1, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $250 → $225 | $143.31 | +57.00% | 5 | Feb 16, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $75 → $30 | $1.77 | +1,594.92% | 9 | Feb 15, 2024 | |
| SYBX Synlogic | Downgrades: Neutral | n/a | $1.87 | - | 5 | Feb 9, 2024 | |
| BTTX Better Therapeutics | Reiterates: Buy | $9 | $0.01 | +89,900.00% | 6 | Aug 10, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $60 | $22.12 | +171.25% | 8 | Aug 8, 2023 | |
| MESO Mesoblast | Maintains: Sell | $8 → $6 | $6.24 | -3.85% | 7 | Aug 4, 2023 | |
| EVLO Evelo Biosciences | Downgrades: Neutral | $50 | $0.05 | +100,910.10% | 3 | Nov 16, 2022 | |
| PHGE BiomX | Maintains: Buy | $6 → $2 | $0.35 | +471.43% | 4 | Nov 10, 2022 | |
| EBS Emergent BioSolutions | Maintains: Buy | $65 → $55 | $1.92 | +2,764.58% | 8 | Nov 9, 2022 | |
| NBSE NeuBase Therapeutics | Downgrades: Neutral | n/a | $0.44 | - | 5 | Oct 17, 2022 | |
| XCUR Exicure | Maintains: Neutral | $0.25 → $2 | $0.50 | +299.92% | 3 | Aug 16, 2022 | |
| FBRX Forte Biosciences | Upgrades: Neutral | n/a | $0.72 | - | 2 | Sep 20, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | n/a | $1.28 | - | 2 | Feb 9, 2021 | |
| OCX OncoCyte | Downgrades: Neutral | n/a | $2.48 | - | 2 | Jun 30, 2020 |
SAB Biotherapeutics
Apr 16, 2024
Maintains: Buy
Price Target: $25
Current: $4.33
Upside: +477.37%
Notable Labs
Apr 15, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $0.97
Upside: +625.39%
Allurion Technologies
Apr 4, 2024
Initiates: Buy
Price Target: $5
Current: $1.92
Upside: +160.42%
Femasys
Apr 1, 2024
Maintains: Buy
Price Target: $12
Current: $1.27
Upside: +844.88%
Omega Therapeutics
Apr 1, 2024
Maintains: Buy
Price Target: $12 → $7
Current: $2.27
Upside: +208.37%
Orchestra BioMed Holdings
Mar 28, 2024
Maintains: Buy
Price Target: $20
Current: $4.39
Upside: +355.58%
Gain Therapeutics
Mar 27, 2024
Reiterates: Buy
Price Target: $6
Current: $3.03
Upside: +98.02%
Coya Therapeutics
Mar 20, 2024
Maintains: Buy
Price Target: $11 → $14
Current: $8.60
Upside: +62.79%
Silence Therapeutics
Mar 14, 2024
Maintains: Buy
Price Target: $26 → $42
Current: $21.61
Upside: +94.40%
ProQR Therapeutics
Mar 14, 2024
Maintains: Buy
Price Target: $2 → $2.5
Current: $1.94
Upside: +28.87%
Dyne Therapeutics
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $31
Current: $24.73
Upside: +25.35%
Seres Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.83
Upside: +869.70%
Avidity Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $23 → $33
Current: $24.36
Upside: +35.47%
Arbutus Biopharma
Mar 1, 2024
Reiterates: Buy
Price Target: $4
Current: $2.73
Upside: +46.52%
Alnylam Pharmaceuticals
Feb 16, 2024
Maintains: Buy
Price Target: $250 → $225
Current: $143.31
Upside: +57.00%
Sonnet BioTherapeutics Holdings
Feb 15, 2024
Maintains: Buy
Price Target: $75 → $30
Current: $1.77
Upside: +1,594.92%
Synlogic
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.87
Upside: -
Better Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $9
Current: $0.01
Upside: +89,900.00%
Arrowhead Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $60
Current: $22.12
Upside: +171.25%
Mesoblast
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $6.24
Upside: -3.85%
Evelo Biosciences
Nov 16, 2022
Downgrades: Neutral
Price Target: $50
Current: $0.05
Upside: +100,910.10%
BiomX
Nov 10, 2022
Maintains: Buy
Price Target: $6 → $2
Current: $0.35
Upside: +471.43%
Emergent BioSolutions
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $1.92
Upside: +2,764.58%
NeuBase Therapeutics
Oct 17, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.44
Upside: -
Exicure
Aug 16, 2022
Maintains: Neutral
Price Target: $0.25 → $2
Current: $0.50
Upside: +299.92%
Forte Biosciences
Sep 20, 2021
Upgrades: Neutral
Price Target: n/a
Current: $0.72
Upside: -
Ocugen
Feb 9, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
OncoCyte
Jun 30, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.48
Upside: -